Developing Durable Therapies to Break the Pattern of Obesity This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the promise and potential impact of our preclinical or clinical trial data, the design, initiation, timing and results of cli ...

On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.“Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company,” said Robert Michael, CEO of AbbVie.Also Read: Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Sh ...

Core Insights - The stock price of Novo Nordisk has significantly decreased after a strong performance in 2024, but it is expected to recover and grow further in the coming years [1] Industry Overview - The obesity rate in the U.S. has more than doubled from 1990 to 2022, rising from slightly over 21% to nearly 44% [2] - Globally, obesity affected over 1 billion people in 2022, leading to an expected surge in sales of weight loss drugs, which exceeded $30 billion worldwide for the first time in 2024 [3] - Morgan Stanley has revised its forecast for weight loss drug sales in 2030 from $77 billion to a range of $105 billion to $144 billion, indicating a potential threefold increase in less than a decade [4] Competitive Landscape - Novo Nordisk and Eli Lilly are the leading companies in the U.S. weight loss drug market, with Eli Lilly's Zepbound as a notable competitor [5] - The approval process for new medications in major markets like the U.S. and the EU is lengthy, giving established products like Wegovy an advantage [6] - Even if Novo Nordisk faces competition from Eli Lilly or new entrants, it is likely to maintain a significant market share in a rapidly growing industry [6]